针对BCMA/CD47的通用CAR-T细胞在多发性骨髓瘤中表现出卓越的抗瘤活性
Qizhong Lu1, Hexian Li1, Zhiguo Wu1
1Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
研究人员开发了新的BCMA/CD47导向的通用CAR-T (UCAR-T) 细胞,以克服对多发性骨髓瘤自主CAR-T治疗的局限性. 这些UCAR-T细胞在体外和体内表现出强大的抗髓瘤活性,提供了一个有前途的"现成"免疫疗法策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 自体仿真抗原受体T (CAR-T) 细胞在复发性或耐火性多发性髓瘤 (RRMM) 中显示出有效性.
- 目前的自主CAR-T细胞制备复杂且昂贵.
- 多发性骨髓瘤中CD47升调表明,准这种途径是有益的.
研究的目的:
- 开发BCMA/CD47导向的通用CAR-T (UCAR-T) 细胞,以解决自身CAR-T疗法的局限性.
- 为了创建一种"现成"的多发性骨髓瘤细胞免疫疗法.
主要方法:
- 用体显示技术对纳米体进行了BCMA和CD47.7的查.
- 使用CRISPR/Cas9系统破坏TRAC和B2M基因,产生TCR和HLA双重淘汰T细胞.
- 开发了BCMA/CD47导向的UCAR-T细胞,并评估了它们的抗瘤活性在体外和体内.
主要成果:
- 针对BCMA和CD47的特定纳米体被确定.
- 针对BCMA/CD47的UCAR-T细胞显示出高的CAR表达 (89.13-98.03%).
- 这些UCAR-T细胞在体外有效地杀死多发性骨髓瘤细胞,并在体内表现出显著的抗瘤活性,延长了瘤移植小鼠的存活时间.
结论:
- 针对BCMA/CD47的UCAR-T细胞对多发性髓瘤表现出强大的抗瘤活性.
- 这种方法为开发新型"现成"细胞免疫疗法提供了潜在的战略.
- 开发的UCAR-T细胞代表了多发性骨髓瘤治疗的有希望的进步.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
